Notificación específica por el Miembro importador de la información requerida en el marco del Sistema de Licencias Obligatorias Especiales - Ver detalles del documento

The following notification from Rwanda's Government Centre for the Treatment & Research on AIDS (TRAC) has been received from the Delegation of Rwanda on 17 July 2007 for circulation to the Council for TRIPS. _______________ Based on Rwanda's present evaluation of its public health needs, we expect to import during the next two years 260,000 packs of TriAvir, a fixed-dose combination product of Zidovudine, Lamivudine and Nevirapine (hereinafter referred to as the "Product") manufactured in Canada by Apotex, Inc. However, because it is not possible to predict with certainty the extent of the country's public health needs, we reserve the right to modify the foregoing estimate as necessary or appropriate. Pursuant to Paragraph 7 of the Doha Declaration and implementation thereof by the TRIPS Council (Decision of the Council for TRIPS of 27 June 2002), we have decided that we will not enforce rights provided under Part II Section 5 of the TRIPS Agreement that may have been granted within Rwanda's territory with respect to the Product.

Lista de producto(s) necesario(s)

Nombre del producto Cantidad del producto  
Actualmente no hay ningún elemento en la base de datos
TriAvir, a fixed-dose combination product of Zidovudine, Lamivudine
260,000 packs

Detalles de la notificación

*Los PMA no están obligados a escoger una de las opciones supra respecto de las capacidades de fabricación.